8-K: Iridex Reports Strong Q3 2025 Growth, Eyes Full-Year Profitability

Iridex Corporation announced an 8% year-over-year revenue increase to $12.5 million for Q3 2025, driven by strong Cyclo G6 and Retina product sales, alongside reduced operating expenses.

Summary

• Total revenue for Q3 2025 reached $12.5 million, an 8% increase year-over-year compared to $11.6 million in Q3 2024.
• Cyclo G6 product family revenue grew 13% year-over-year to $3.5 million, with 14,900 probes and 30 laser systems sold.
• Retina product revenue increased 4% year-over-year to $6.7 million.
• Operating expenses were reduced by 12% to $5.4 million in Q3 2025, primarily due to headcount reductions and project postponements.
• Net loss improved to $1.6 million ($0.09 per share) in Q3 2025 from $1.9 million ($0.12 per share) in Q3 2024.
• Non-GAAP adjusted EBITDA improved significantly to a loss of $131 thousand in Q3 2025, compared to a loss of $1.4 million in Q3 2024.
• Cash and cash equivalents stood at $5.6 million as of September 27, 2025, a reduction of $1.2 million during the quarter.
• Gross profit was $4.0 million (32.1% gross margin), a decrease of $0.3 million compared to $4.3 million (37.3% gross margin) in the prior year, primarily due to an $0.8 million non-recurring inventory write-down.

Sentiment

Score: 8

Explanation: The company demonstrated strong year-over-year revenue growth, significant operating expense reductions, and a substantial improvement in adjusted EBITDA, moving closer to full-year profitability. The positive outlook for sustained cash flow and full-year adjusted EBITDA positivity is a strong indicator. However, a quarterly reduction in cash and a one-time inventory write-down impacting gross margin temper the overall positive sentiment slightly.

Positives

• Achieved 8% year-over-year total revenue growth in Q3 2025.
• Cyclo G6 product family revenue increased by 13% year-over-year.
• Retina product revenue showed a 4% year-over-year increase.
• Operating expenses were significantly reduced by 12% year-over-year.
• Net loss improved from $1.9 million to $1.6 million year-over-year.
• Non-GAAP adjusted EBITDA improved by $1.3 million year-over-year, moving closer to profitability.
• The company expects to achieve adjusted EBITDA positive for the full year 2025 and sustained cash flow positivity going forward.
• Stockholders' equity increased from $2.097 million as of December 28, 2024, to $4.681 million as of September 27, 2025.

Negatives

• Gross profit decreased by $0.3 million year-over-year, and gross margin declined by 520 basis points to 32.1% due to an $0.8 million non-recurring inventory write-down.
• Cash and cash equivalents decreased by $1.2 million during Q3 2025, ending at $5.6 million.
• Medical and surgical retina system sales were lower, partially offsetting growth in other areas.

Risks

• The company's ability to achieve future performance is subject to various factors, including clinical expectations, commercial trends, market adoption and expansion, value-maximizing transactions, and demand for products.
• There is no assurance that the company will complete any value-maximizing transactions on behalf of its stockholders.
• Actual results may differ materially from forward-looking statements due to a number of factors.
• Detailed risks are described in the Risk Factors section of Iridex's most recent Annual Report on Form 10-K and other SEC filings.

Future Outlook

The company expects to continue improving its financial performance by reducing operational costs. It anticipates achieving adjusted EBITDA positive for the full year 2025 and sustained cash flow positivity going forward, with plans to reach cash flow breakeven in the fourth quarter of 2025 on revenue generation consistent with 2024.

Management Comments

• "I am extremely proud of what our team has accomplished in my first year as CEO."
• "For the fourth consecutive quarter, we have achieved year-over-year revenue growth, reduced operating expenses and improved adjusted EBITDA."
• "Our third quarter results represent strength across the business with growth led by G6 probe and Pascal retina laser system sales."
• "Looking ahead, we expect to continue improving the financial performance of our business, in part, by continuing to reduce our costs of operations."
• "As a result of the Company's much reduced cost structure, we expect to be adjusted EBITDA positive for the full year 2025 and that our balance sheet will support sustained cash flow positivity for Iridex going forward."

Industry Context

Iridex operates in the ophthalmology market, specializing in innovative laser-based medical systems for glaucoma and retinal diseases. As a worldwide leader in this niche, the company's continued revenue growth and focus on cost reduction align with broader trends in the medical device industry where efficiency and specialized technology drive market share. The growth in Cyclo G6 and Pascal retina laser systems indicates strong demand for advanced, minimally invasive treatments for sight-threatening eye conditions.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability metrics (net loss, adjusted EBITDA), and a positive outlook for future cash flow and full-year adjusted EBITDA. The increase in stockholders' equity is also positive.
• Employees: Potential impact from past expense reduction measures, including headcount reductions in late 2024, but current focus is on continued cost reduction.
• Customers: Continued availability of innovative laser-based medical systems for glaucoma and retinal diseases, with growth in key product lines.
• Creditors: Improved financial health and outlook for sustained cash flow positivity could enhance creditworthiness.

Next Steps

• Host a conference call on November 11, 2025, at 2:00 p.m. PT / 5:00 p.m. ET to discuss results.
• Continue improving financial performance by reducing costs of operations.
• Achieve cash flow breakeven in the fourth quarter of 2025.
• Achieve positive adjusted EBITDA for the full year 2025.
• Support sustained cash flow positivity going forward.

Key Dates

Recommendation

The company has demonstrated consistent year-over-year revenue growth for four consecutive quarters, coupled with aggressive and effective operating expense reductions. The significant improvement in adjusted EBITDA, moving from a substantial loss to near breakeven in Q3, and the explicit guidance for full-year 2025 adjusted EBITDA positivity and sustained cash flow positivity, indicate a strong turnaround and positive momentum. While a one-time inventory write-down impacted gross margin, the underlying operational improvements and strategic focus on cost control are compelling. The increase in stockholders' equity also reflects a strengthened balance sheet. These factors suggest a strong investment opportunity for long-term growth.

Keywords

Iridex, IRIX, Financial Results, Q3 2025, Glaucoma, Retinal Diseases, Laser Medical Systems, MicroPulse, Adjusted EBITDA, Revenue Growth, Ophthalmology